Insys Therapeutics (INSY) Sets New 52-Week Low at $5.04

Insys Therapeutics Inc (NASDAQ:INSY) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $5.04 and last traded at $5.12, with a volume of 35132 shares trading hands. The stock had previously closed at $5.32.

INSY has been the subject of a number of analyst reports. ValuEngine lowered shares of Insys Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 21st. Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 11th. Piper Jaffray Companies set a $4.00 target price on shares of Insys Therapeutics and gave the stock a “sell” rating in a report on Saturday, August 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $10.00 target price on shares of Insys Therapeutics in a report on Friday, August 10th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.67.

The firm has a market capitalization of $381.75 million, a price-to-earnings ratio of -10.57 and a beta of 1.58.

Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Monday, November 5th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.30 million for the quarter, compared to analysts’ expectations of $24.05 million. Insys Therapeutics had a negative return on equity of 266.60% and a negative net margin of 128.88%. The business’s revenue for the quarter was down 40.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.30) earnings per share. As a group, equities research analysts predict that Insys Therapeutics Inc will post -1.32 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Insys Therapeutics by 4.7% in the third quarter. Vanguard Group Inc. now owns 2,661,324 shares of the specialty pharmaceutical company’s stock worth $26,825,000 after buying an additional 119,776 shares during the period. MetLife Investment Advisors LLC purchased a new stake in Insys Therapeutics in the third quarter worth about $223,000. BlueMountain Capital Management LLC lifted its holdings in Insys Therapeutics by 533.6% in the third quarter. BlueMountain Capital Management LLC now owns 28,145 shares of the specialty pharmaceutical company’s stock worth $284,000 after buying an additional 23,703 shares during the period. Jane Street Group LLC purchased a new stake in Insys Therapeutics in the third quarter worth about $113,000. Finally, Bridgeway Capital Management Inc. lifted its holdings in Insys Therapeutics by 11.2% in the third quarter. Bridgeway Capital Management Inc. now owns 84,700 shares of the specialty pharmaceutical company’s stock worth $854,000 after buying an additional 8,500 shares during the period. Institutional investors and hedge funds own 17.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insys Therapeutics (INSY) Sets New 52-Week Low at $5.04” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2018/12/08/insys-therapeutics-insy-sets-new-52-week-low-at-5-04.html.

Insys Therapeutics Company Profile (NASDAQ:INSY)

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

See Also: Do Tariffs Work?

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit